The Catalyst

Most Recent Posts

02.24.15 | By Jay Taylor

Understanding how intrinsic intellectual property (IP) is to the United States economy (innovative industries support more than a quarter of all jobs in the U.S.), the Office of the U.S.

02.23.15 | By Allyson Funk

According to the Centers for Disease Control and Prevention, one in three American adults has high cholesterol. For those struggling with high cholesterol, getting needed prescriptions and adhering to the prescribed treatment regimen is critical.

02.19.15 | By Dr. Bill Chin

I am excited to be in India this week to discuss the scientific landscape of pharmaceutical research and development. Everywhere I go I see so much potential for India to become a leader in the discovery and development of innovative medicines. India has a large cadre of well-trained pharmaceutical scientists and has more U.S.

02.18.15 | By Eileen Cannon

For 50 years, the PhRMA Foundation has supported young scientists in their efforts to pursue careers in research and education that will ultimately lead to improved care and treatment options for patients.

02.16.15 | By Allyson Funk

Managing diabetes treatments is a big task. Medicare Part D helps patients access needed medicines, keeps costs low and helps avoid costly hospitalizations and complications.

02.13.15 | By Christian Clymer

The internet provides us with a wealth of information right at our fingertips, but it’s important to be mindful of misinformation, especially as it pertains to your health. With myths and facts swirling about important health topics this week, we cut through the clutter to bring you the facts.

02.11.15 | By Allyson Funk

Last year, PhRMA was joined by patient groups to highlight an analysis that found a majority of plans in health insurance exchanges required relatively high cost sharing for all medicines in at least one class. The cost burden leaves many patients with no other option, forcing them to make tough choices or go without needed medicines, ultimately having a negative impact on their health.

02.10.15 | By Dr. Bill Chin

Last week, Food and Drug Administration (FDA) Commissioner Margaret Hamburg announced that she will step down from her post at the end of next month. PhRMA and its member companies appreciate Commissioner Hamburg’s years of dedication to health care innovation that helps America’s patients.


By Jennifer Bryant

According to a new report from actuaries Gabriela Dieguez, Bruce Pyenson and Jennifer Carioto, at Milliman, major pharmacy benefits managers (PBMs) often overestimate future spending on specialty medicines, sometimes by nearly 10 percentage points.

02.09.15 | By Allyson Funk

When a Medicare Part D beneficiary adheres to their prescription regimen, both the individual and the broader health care system benefit. The Congressional Budget Office (CBO), for example, now estimates increasing the number of Part D prescriptions filled by just 1 percent reduces program spending on medical services by approximately 0.20 percent. The cost savings are even greater for seniors with certain chronic conditions. Today, we’re looking at congestive heart failure.

02.06.15 | By Christian Clymer

In recent years, the development of new medicines has helped transform the lives of patients. But lives cannot be improved without access to those innovative treatments. We support helping patients get access to what they need to live happier, healthier lives, and it was our focus this week.

02.05.15 | By Karyn Schwartz

Did you know health insurance exchange plans are allowed to drop coverage of medications from their formularies midyear? Early evidence indicates that some health insurance exchange or marketplace plans are taking advantage of this flexibility and significantly reducing access to needed medications.


By Anne Pritchett, PhD

As we enter the second half of the decade, the biopharmaceutical industry’s approach to research and development (R&D) continues to evolve to meet the growing demand for new medicines.

02.04.15 | By Tina Stow

Today is World Cancer Day, and 2015’s “Not beyond us” theme highlights an incredibly important message: we’re making tremendous advances in the fight against cancer and continued progress means a future with a cure could be right around the corner. America’s biopharmaceutical research companies are dedicated to achieving this outcome and improving the quality of patients’ lives through pioneering medicines and enabling access to those treatments. 

02.03.15 | By Robert Zirkelbach

Research and development (R&D) is the backbone of the biopharmaceutical industry and the reason why we have seen more than 450 new medicines approved in the U.S.